Wednesday, October 14, 2026
23.7 C
Bengaluru

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business unit. It was a scientific outpost.

I entered this field when we measured success by the depth of a clinical conversation, not the breadth of a CRM dashboard. Today, oncology is a multi-billion-dollar strategic chess match. But as we have gained scale, there is a lingering question: have we lost the plot?

Looking back at four decades from the frontlines, the evolution of cancer care in India was not a slow climb. It was a series of radical rewiring events that changed how we think, sell, and treat.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

With over two decades of experience across finance, strategy,...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of...

The Great Healthcare Dilemma: Who Will Own the Next Indian Hospital?

The next owner of an Indian hospital may not...

Indian Pharma’s Three Deficits—and Three Potential Dividends

Indian pharma has already done the hard thing once. It...

Topics

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of...

Indian Pharma Is Two Industries Wearing One Label

Indian pharma is often discussed as one sector. In...

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...
spot_img

Related Articles

spot_imgspot_img